

Ref. RPQ/REG/ISF/Alert N°4,2020

09 April 2020

UPDATE (of 9 June 2020) to Medical Product Alert n°4/2020

## **Medical Product Alert N°4/2020**

Falsified chloroquine products circulating in the WHO regions of Africa and Europe

This Medical Product Alert relates to several confirmed falsified chloroquine products circulating in the WHO regions of Africa and Europe. New reports of falsified chloroquine which have been validated by WHO are included in this update.

Between 31 March and 14 April 2020, the WHO <u>global surveillance and monitoring system on substandard and falsified (SF) medical products</u> received 14 reports of confirmed falsified chloroquine products from 5 countries: Burkina Faso, Cameroon, Democratic Republic of Congo, France, and Niger. All reported products were identified at patient level and all have been confirmed as falsified.

Widespread vigilance is required from all countries, regardless of where the product was originally identified.

All the products (with photographs) listed in the annex are confirmed as falsified, on the basis that they deliberately/fraudulently misrepresent their identity, composition or source. Indeed, it can be noted that:

- <u>EITHER</u>: the products do not contain the correct amount of the active pharmaceutical ingredient, based on the results of preliminary or full compendial analysis;
- <u>AND/OR</u>: the products were not produced by the manufacturer whose name is stated on the product labels, and the variable data (batch number and dates) of the above products do not correspond to genuine manufacturing records;
- AND/OR: the manufacturer whose name is stated on the product labels does not exist.

Chloroquine phosphate or sulfate is referenced on the WHO Model List of Essential Medicines for the treatment of Plasmodium vivax infection (malaria). Large clinical trials are under way to generate the robust data needed to establish the efficacy and safety of chloroquine and hydroxychloroquine in the treatment of COVID-19. These medicines are currently authorized for malaria and certain autoimmune diseases and it is important that patients do not face shortages caused by stockpiling or use outside the authorized indications. Both chloroquine and hydroxychloroquine can have serious side effects, especially at high doses or when combined with other medicines.

The <u>SOLIDARITY trial</u>, led by WHO, is reviewing potential treatments for COVID-19. Please refer to <u>WHO medical product alert n°3/2020</u> for general information on falsified medical products in relation to the management of COVID-19.

WHO requests increased vigilance within the supply chains of countries likely to be affected by these falsified products. Increased vigilance should include hospitals, clinics, health centres, wholesalers, distributors, pharmacies and any other suppliers of medical products.

All medical products must be obtained from licensed, authentic and reliable sources. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional in case of doubt.

If you are in possession of the above products, please do not use. If you have used these falsified products, or you suffered an adverse reaction/event having used these products, you are advised to

20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

seek immediate medical advice from a qualified healthcare professional, and to report the incident to the National Regulatory Authorities/National Pharmacovigilance Centre.

National regulatory/health authorities are advised to immediately notify WHO if these falsified products are discovered in their country. If you have any information concerning the manufacture, distribution, or supply of these products, please contact <a href="mailto:rapidalert@who.int">rapidalert@who.int</a>.

**ANNEX** 

Updated list of falsified chloroquine products, subject of WHO Alert N°4/2020, with additional products identified in Burkina Faso, Cameroun, and France

PRODUCT NAME	PRODUCT INFORMATION	IDENTIFIED IN	PHOTOGRAPHS
CHLOROQUINE PHOSPHATE (100MG)	Stated Manufacturer: Jiangsu Pharmaceutical Inc Batch N°: 660 Exp date: 05/2021 Mfg date: 05/2017	Cameroon	Characterisms and of prophysical Characterisms and of prophysical Characterisms and of prophysical Characterisms and prophysic
CHLOROQUINE PHOSPHATE (250MG)	Stated Manufacturer: Jiangsu Pharmaceutical Inc Batch N°: 660 Exp date: 09/2022 Mfg date: 09/2022	Cameroon	Tablets U.S.P.  Batch Not Mig. D.  Mig.
CHLOROQUINE PHOSPHATE 250MG	Stated Manufacturer: Astral pharmaceuticals Batch N°: EBT 2542 Exp date: 10/2022 Mfg date: 01/2019	Cameroon	CHLOROQUINE PHOSPHATE  250 MG TABLETS  Convert do star of the star

CHLOROQUINE PHOSPHATE TABLETS (100MG)	Stated Manufacturer: Jiangsu Pharmaceutical Inc Batch N°: 660 Exp date: 08/2022 Mfg date: 08/2018	Cameroon	Chloroquine Phosphate Tablets U.S.P.  See See Control  Characterist U.S.P. 100mg  Bach ho 68  See See Control
CHLOROQUINE PHOSPHATE TABLETS (100MG)	Stated Manufacturer: Jiangsu Pharmaceutical Inc Batch N°: 660 Exp date: 04/2023 Mfg date: 05/2019	Cameroon	Chloroquine Phosphate Tablets (J.S. P.  When the state of
CHLOROQUINE PHOSPHATE TABLETS BP 100MG	Stated Manufacturer: None indicated Batch N°: Not legible Exp date: 06/2022 Mfg date: 07/2019	Burkina Faso	CHLOROQUINE PHOSPHATE TABLETS B.P. 100 MG  10 x 10 Tabletr Antimalarial Tablets
CHLOROQUINE PHOSPHATE TABLETS BP 100MG	Stated Manufacturer: None indicated Batch N°: ET9274 Exp date: 05/2022 Mfg date: 06/2019	Burkina Faso	CHLOROQUINE PHOSPHATE TABLETS 100 MG  10 X 10 Tablets  Artimalarial Tablates
CHLOROQUINE PHOSPHATE TABLETS BP 100MG	Stated Manufacturer: None indicated Batch N°: 05 Exp date: 06/2022 Mfg date: 07/2019	Burkina Faso	CHLOROQUINE PHOSPHATE TABLETS B.P. 100 MG  10 x 10 Tablets  Antimalarial Tablets

NIRUQUINE (100MG)	Stated Manufacturer: None indicated Batch N°: Not legible Exp date: 08/2022 Mfg date: 09/2019	Burkina Faso, France, Niger	Niruquine Chloroquine Phosphate Tablets 100 mg  10X10 Comprimés Tablets  Antimalarial Tablets  Antimalarial Tablets  Voie orale - For orale use Voir la notice intérieure see package insert. Cocheque comprimé contient : Each uncoatlet fablet contains : Chicroquine phosphate B.P. 100 mg Excipients : Store below 30 °C Dossage : As directed by the physician. Ne pas laisser a la portee des enfants. Keep out of reach of children
CLOROQUINE 250MG	Stated Manufacturer: Dawa Limited Batch N°: 1605059 Exp date: 04/2023 Mfg date: 05/2019	Democratic Republic of Congo	I 1000 Tablets/Carprinet/C
CHLOROQUINE PHOSPHATE 250MG	Stated Manufacturer: Brown & Burk Pharmaceutical Limited Batch N°: 065622 Exp date: 11/2022 Mfg date: 11/2018	Democratic Republic of Congo	TABLES 1000 COMPRIMES CHLOROQUINE PHOSPHATESS  ANTHANA ARRA  Entitle Companies Divine Storing United by Frince bisses 30°C and generated from light and of which of chargems  Broad and which
SAMQUINE 100 (100MG)	Stated Manufacturer: None indicated Batch N°: NBJT01 Exp date: Oct-2022 Mfg date: Nov-2019	France, Niger	SAMQUINE 100 CHLOROQUINE PHOSPHATE COMPRIMÉS BP 100 MG  10 x 10 Tablets  Antimalarial Tablets

20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

CHLOROQUINE PHOSPHATE TABLETS B.P 100MG	Stated Manufacturer: None indicated Batch N°: NBJT02 Exp date: Oct-2022 Mfg date: Nov-2019	France, Niger	CHLOROQUINE PHOSPHATE TABLETS B.P. 100 MG  15 x 10 Tablets  Artimalarial Tablets
CHLOROQUINE PHOSPHATE TABLETS B.P 100MG	Stated Manufacturer: None indicated Batch N°: HV1116 Exp date: May 2023 Mfg date: June 2019	Niger	CHLOROQUINE PHOSPHATE TABLETS B.P. 100 MG  Antimalarial Tablets

## WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products

For more information, please visit: <a href="www.who.int/medicines/regulation/ssffc/en/">www.who.int/medicines/regulation/ssffc/en/</a> Email: rapidalert@who.int